... growing interest in insulin-likegrowth fa ctor 1 receptor (IGF1R) in medical oncology.IGF1R is a tyrosine kinase receptor that binds bothIGF1 and IGF2 [1]. After ligand binding, the tyrosinekinase ... pathway inhibition byADW742, alone or in combination with imatinib, doxorubicin, orvincristine, is a novel therapeutic approach in Ewing tumor. Clin CancerRes 2006, 12:3532-40.31. Kim WY, Jin ... the original work is properly cited.inhibitors that block the intracellular tyrosine kinase. In theory, if they work both should bloc k receptor activa-tion, and thereby block the intracellular...